Specialty Pharmacy

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

The combination therapy reduced the risk of squamous cell carcinoma development on the face and scalp by approximately 75% in the study.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care industry.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Certolizumab pegol (Cimzia) is the first FDA-approved therapy for this type of axial spondyloarthritis, filling an unmet clinical need for treatment options.

An updated transmission model indicates that most new HIV infections occur due to a lack of diagnosis and treatment.

Top news of the day from across the health care industry.

According to the study, enzyme USP15 may regulate cancer cell response to poly-(ADP-ribose) polymerase inhibitors.

An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.

Officials with the FDA approved Wednesday testosterone undecanoate (Jatenzo, Clarus Therapeutics), an oral testosterone capsule for treating men with certain forms of hypogonadism.

Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease.

Program uses archived samples from patients with known treatment outcomes to accelerate research in predicting therapeutic responses for future patients with cancer.

Managed Health Care Associates’ Annual Business Summit covers wide range of topics, including insights on managing cost and improving operational efficiencies.

Top news of the day from across the health care industry.

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

Preventive drugs are frequently continued in patients with cancer near end of life despite limited clinical benefit.

Study finds older patients administered combined immunosuppression experienced similar remission of Crohn disease as those aged under 60 years.

Top news of the day from across the health care industry.

Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.

The findings could help promote interventions aimed at improving patient and provider confidence in generic drugs for managing chronic diseases.

Study is the first and largest of its kind to examine mortality associated with beta interferons, the first drugs to be approved for the treatment of relapsing-onset multiple sclerosis.

Top news of the day from across the health care industry.

Chris Kepinski, PharmD, sat down with Specialty Pharmacy Times at the National Community Oncology Dispensing Association conference in Denver, Colorado to discuss how treatment support kits act a vital resource for patients throughout their treatment.

A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.

Interim phase 3 trial results showed an increased risk of death for patients receiving venetoclax for multiple myeloma.

Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.

A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care industry.